Rosiglitazone in diabetes control in hemodialysis patients with and without viral hepatitis infection: Effectiveness and side effects

Diabetes Care

Volumn 30, Issue 1, 2007, Pages 3-7

  Chiang, Chih Kang ^a,b   Ho, Tai I ^b   Peng, Yu Sen ^b   Hsu, Shih Ping ^b   Pai, Mei Fen ^b   Yang, Shao Yu ^b   Hung, Kuan Yu ^a   Wu, Kwan Dun ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b FAR EASTERN MEMORIAL HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADIPONECTIN; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; C REACTIVE PROTEIN; CHOLESTEROL; HEMOGLOBIN A1C; HEPATITIS B SURFACE ANTIGEN; HEPATITIS C ANTIBODY; INSULIN; ORAL ANTIDIABETIC AGENT; ROSIGLITAZONE; TRIACYLGLYCEROL;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD PRESSURE; CARDIOVASCULAR FUNCTION; CHOLESTEROL BLOOD LEVEL; CHRONIC HEPATITIS; CONTROLLED STUDY; DIABETES CONTROL; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HEART FAILURE; HEART PROTECTION; HEMODIALYSIS; HEMOGLOBIN BLOOD LEVEL; HEPATITIS B; HEPATITIS C; HUMAN; HYPOGLYCEMIA; INSULIN RESISTANCE; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COMPLIANCE; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN;

C-REACTIVE PROTEIN; COHORT STUDIES; DIABETES MELLITUS; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; FEMALE; FOLLOW-UP STUDIES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RENAL DIALYSIS; SAFETY; THIAZOLIDINEDIONES; VIRUS DISEASES;

EID: 33846003119     PISSN: 01495992     EISSN: 01495992     Source Type: Journal    
DOI: 10.2337/dc06-0956     Document Type: Article

References (20)

1. U.S. renal data system, USRDS 2004 annual data report [article online]. Available from http://www.usrds.org/2004/pdf/13_intl_04.pdf. Accessed 10 March 2006
2. Wong TY, Szeto CC, Chow KM, Leung CB, Lam CW, Li PK: Rosiglitazone reduces insulin requirement and C-reactive protein levels in type 2 diabetic patients receiving peritoneal dialysis. Am J Kidney Dis 46:713-719, 2005
3. Campbell IW: The clinical significance of PPARγ agonism. Curr Mol Med 5:349-363, 2005
4. Cheng SC, Chu TS, Hung KY, Chen YM, Chang WK, Tsai TJ, Wu KD: Association of hypertriglyceridemia and insulin resistance in uremic patients undergoing CAPD. Perit Dial Int 21:282-229, 2001
5. Huang JW, Yen CJ, Chiang HW, Hung KY, Tsai TJ, Wu KD: Adiponectin in peritoneal dialysis patients: a comparison with hemodialysis patients and subjects with normal renal function. Am J Kidney Dis 43:1047-1055, 2004
6. Hetzel J, Balletshofer B, Rittig K, Walcher D, Kratzer W, Hombach V, Haring HU, Koenig W, Marx N: Rapid effects of rosiglitazone treatment on endothelial function and inflammatory biomarkers. Arterioscler Thromb Vasc Biol 25:1804-1809, 2005
7. Goldberg RB, Kendall DM, Deeg MA, Buse JB, Zagar AJ, Pinaire JA, Tan MH, Khan MA, Perez AT, Jacober SJ, the GLAI Study Investigators: A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 28:1547-1554, 2005
8. Nesto RW, Bell D, Bonow RQ, Fonseca V, Grandy SM, Horton ES, Le Winter M, Porte D, Semenkovich CF, Smith S, Young LH, Kahn R: Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and the American Diabetes Association. Circulation 108:2941-2948, 2003
9. Home PD, Pocock SJ, Beck-Nielsen H, Gomis R, Hanefeld M, Dargie H, Komajda M, Gubb J, Biswas N, Jones NP: Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes (RECORD): study design and protocol. Diabetologia 48:1726-1735, 2005
10. Chalasani N, Teal E, Hall SD: Effect of rosiglitazone on serum liver biochemistries in diabetic patients with normal and elevated baseline liver enzymes. Am J Gastroenterol 100:1317-1321, 2005
11. Menees SB, Anderson MA, Chensue SW: Hepatic injury in a patient taking rosiglitazone. J Clin Gastroenterol 39:638-640, 2005
12. Hung KY, Chen WY, Yang CS, Lee SH, Wu DJ: Hepatitis B and C in hemodialysis patients. Dial Transplant 24:135-139, 1995
13. Hung KY, Shyu RS, Huang CH, Tsai TJ, Chen WY: Viral hepatitis in continuous ambulatory peritoneal dialysis patients in an endemic area for hepatitis B and C infection: the Taiwan experience. Blood Purif 15:195-199, 1997
14. Chiang CK, Hsu SP, Peng YS, Ho TI, Liu SH, Hung KY: Low-density lipoprotein cholesterol associated with morality and hospitalization in hemodialysis patients. Blood Purif 23:134 -140, 2005
15. Peng YS, Chiang CK, Hsu SP, Pai MF, Hung KY, Kao JH: Influence of hepatitis C virus infection on soluble cellular adhesion molecules in hemodialysis patients. Blood Purif 23:106 -112, 2005
16. Sarafidis PA, Lasaridis AN, Nilsson PM, Mouslech TF, Hitoglou-Makedou AD, Stafylas PC, Kazakos KA, Yovos JG, Tourkantonis AA: The effect of rosiglitazone on novel atherosclerotic risk factors in patients with type 2 diabetes mellitus and hypertension: an open-label observational study. Metabolism 54:1236-1242, 2005
17. Haffner SM, Greenberg AS, Weston WM, Chen H, Williams K, Freed MI: Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 106:679-684, 2002
18. Lin SH, Lin YF, Kuo SW, Hsu YJ, Hung YJ: Rosiglitazone improves glucose metabolism in nondiabetic uremic patients on CAPD. Am J Kidney Dis 42:774-780, 2003
19. Masoudi FA, Inzucchi SE, Wang Y, Hayranek EP, Foody IM, Krumholz HM: Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observation study. Circulation 111:583-590, 2005
20. Hung KY, Lee KC, Yen CJ, Wu KD, Tsai TJ, Chen WY: Revised cutoff values of serum aminotransferase in detecting viral hepatitis among CAPD patients: experience from Taiwan, and endemic area for hepatitis B. Nephrol Dial Transplant 12:180-183, 1997